# E156 Protocol — `ctgov-registry-survival`

This repository is the source code and dashboard backing an E156 micro-paper on the [E156 Student Board](https://mahmood726-cyber.github.io/e156/students.html).

---

## `[330]` CT.gov Registry Survival: Kaplan-Meier Analysis of Trial Registration to Completion

**Type:** methods  |  ESTIMAND: Median time from registration to results posting  
**Data:** ClinicalTrials.gov lifecycle data for registered trials

### 156-word body

What is the survival curve for clinical trials from registration through completion to results posting on ClinicalTrials.gov, and which design features predict timely completion? We applied Kaplan-Meier survival analysis to ClinicalTrials.gov lifecycle milestones, treating results posting as the event and ongoing or terminated trials as censored observations. The analysis computed median times from registration to start, start to completion, and completion to results posting, stratified by phase, sponsor class, and therapeutic area. Median time from registration to results posting was 6.8 years (95% CI 6.5 to 7.1) for phase 3 trials, with industry-sponsored trials posting 1.4 years faster than academic-sponsored trials on average. Completion-to-posting delay showed the widest variation, with 25 percent of completed trials still lacking results after 3 years despite FDAAA reporting requirements. Trial lifecycle survival analysis could identify structural bottlenecks in the evidence pipeline from registration through public availability. The analysis uses registry-reported dates which may not accurately reflect actual milestone timing for all trials.

### Submission metadata

```
Corresponding author: Mahmood Ahmad <mahmood.ahmad2@nhs.net>
ORCID: 0000-0001-9107-3704
Affiliation: Tahir Heart Institute, Rabwah, Pakistan

Links:
  Code:      https://github.com/mahmood726-cyber/ctgov-registry-survival
  Protocol:  https://github.com/mahmood726-cyber/ctgov-registry-survival/blob/main/E156-PROTOCOL.md
  Dashboard: https://mahmood726-cyber.github.io/ctgov-registry-survival/

References (topic pack: restricted mean survival time / survival meta-analysis):
  1. Royston P, Parmar MK. 2013. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 13:152. doi:10.1186/1471-2288-13-152
  2. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. 2007. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:16. doi:10.1186/1745-6215-8-16

Data availability: No patient-level data used. Analysis derived exclusively
  from publicly available aggregate records. All source identifiers are in
  the protocol document linked above.

Ethics: Not required. Study uses only publicly available aggregate data; no
  human participants; no patient-identifiable information; no individual-
  participant data. No institutional review board approval sought or required
  under standard research-ethics guidelines for secondary methodological
  research on published literature.

Funding: None.

Competing interests: MA serves on the editorial board of Synthēsis (the
  target journal); MA had no role in editorial decisions on this
  manuscript, which was handled by an independent editor of the journal.

Author contributions (CRediT):
  [STUDENT REWRITER, first author] — Writing – original draft, Writing –
    review & editing, Validation.
  [SUPERVISING FACULTY, last/senior author] — Supervision, Validation,
    Writing – review & editing.
  Mahmood Ahmad (middle author, NOT first or last) — Conceptualization,
    Methodology, Software, Data curation, Formal analysis, Resources.

AI disclosure: Computational tooling (including AI-assisted coding via
  Claude Code [Anthropic]) was used to develop analysis scripts and assist
  with data extraction. The final manuscript was human-written, reviewed,
  and approved by the author; the submitted text is not AI-generated. All
  quantitative claims were verified against source data; cross-validation
  was performed where applicable. The author retains full responsibility for
  the final content.

Preprint: Not preprinted.

Reporting checklist: PRISMA 2020 (methods-paper variant — reports on review corpus).

Target journal: ◆ Synthēsis (https://www.synthesis-medicine.org/index.php/journal)
  Section: Methods Note — submit the 156-word E156 body verbatim as the main text.
  The journal caps main text at ≤400 words; E156's 156-word, 7-sentence
  contract sits well inside that ceiling. Do NOT pad to 400 — the
  micro-paper length is the point of the format.

Manuscript license: CC-BY-4.0.
Code license: MIT.

SUBMITTED: [ ]
```


---

_Auto-generated from the workbook by `C:/E156/scripts/create_missing_protocols.py`. If something is wrong, edit `rewrite-workbook.txt` and re-run the script — it will overwrite this file via the GitHub API._